logo
Share SHARE
FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chinese electric vehicle start-up Nio has launched the NIO ES8, a seven-seater electric SUV, at about half the price of Tesla's Model X. The ES8 is Nio's first mass-produced model for the China market. Founded in 2014, Nio unveiled the ES8 in Beijing on Saturday at a base price of 448,000 yuan, or $68,947, before subsidies. This is only about half the price for Tesla's Model X. Bitcoin futures started trading on the world's largest futures exchange, CME Group Sunday, a week after the launch of the very first bitcoin futures on CBOE. CME's own bitcoin futures contract started trading under the ticker "BTC", with the sale price for its January 2018 contracts opening at $20,650. HEICO Corp. (HEI) and Worthington Industries Inc. (WOR) are slated to release their quarterly results on December 18, 2017.
comments powered by Disqus
Follow RTT